Streetwise Reports' Article Archives — Current Month (22)
Biotech Company Uncovers Breakthrough Canine Arthritis Treatment (03/30/2026)
Israeli co. Can-Fite BioPharma Ltd. (CANF:NYSEAmerican) teamed up with Vetbiolix to trial Piclidenoson for dogs, with Phase 2 results due Q3 2026. Yet, one analyst still rates the stock as a Hold. Read on to see why.
First US Brain-Only PET Clinic Targets Alzheimer's Detection as Diagnostic Demand Expands (03/27/2026)
Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is opening its inaugural brain PET clinic in Florida with a five-year lease and renewal option.
Massachusetts Biotech Co. Finds High-Potential Muscle Treatment Breakthrough (03/27/2026)
Sarepta Therapeutics Inc.'s (SRPT:NASDAQ) early results reveal dose-dependent drug exposure and significant biomarker reductions for forms of muscular dystrophy.
Biotech Company Achieves Key Bladder Cancer Milestone in California (03/27/2026)
ImmunityBio Inc. (IBRX:NASDAQ) confirms study power sufficiency for ANKTIVA combo, supporting measurable response outcomes and maintaining timeline for 2026 BLA filing.
Biotech Price Target Raised on Strong FSHD and DM1 siRNA Data (03/27/2026)
Wedbush Securities raised its price target on Sarepta Therapeutics Inc. (SRPT:NASDAQ), following promising Phase 1/2 data for siRNA candidates SRP-1001 in FSHD and SRP-1003 in DM1, citing superior muscle concentration and a clean safety profile versus rival programs from Novartis and Dyne Therapeutics.
America's First Brain-Dedicated PET Scanning Clinics: A Turnaround Play for Chart-Savvy Investors? (03/26/2026)
Technical Analyst Stewart Thomson explains why he thinks Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is a Strong Speculative Buy.
Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline (03/26/2026)
H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics Inc. (SRPT:NASDAQ), arguing that promising but early-stage siRNA muscle concentration data in DM1 and FSHD cannot compensate for falling ELEVIDYS sales, a fatal adverse event in SRP-1003, and intensifying competition from Avidity and Dyne ahead of a potential 2030 market entry.
Neuroscience Co. Enters Catalyst-Rich 2026 With Multiple Phase 2 Readouts and US$120M Financing (03/25/2026)
H.C. Wainwright reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE), citing upcoming Phase 2 data readouts for ALTO-101, ALTO-300, and ALTO-100, plus US$120 million financing to advance ALTO-207 in treatment-resistant depression through Phase 3.
Buy Rating Reaffirmed: ALTO-207 TRD Trial on Track (03/25/2026)
Stifel reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE) after an in-line Q4 2025 earnings report.
Biotech Company Accelerates AI Detection Breakthrough Globally (03/20/2026)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) advanced AI-powered screening kiosks, targeting safer operations across industrial sectors.
Durham, NC Biopharma Co. Finds High-Growth Drug Opportunity (03/20/2026)
Pelthos Therapeutics Inc. (PTHS:NYSEAmerican) delivered massive growth from its drug launch, with bullish forecasts signaling upside, according to analysts.
Life Sciences Firm Advances Massive US$2.4B Market Opportunity (03/18/2026)
Cleantech and life sciences leader BioLargo Inc. (BLGO:OTCQX) announces that clinical experiences with ViaCLYR were presented at a symposium in Hawaii.
An AI-Powered Doctor & Patient Platform: Why This North American Provider is Gaining Market Momentum (03/17/2026)
Technical Analyst Stewart Thomson explains why he likes Rocket Doctor AI Inc. (AIDR:CSE; TREIF:OTC; 939:FRA).
Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch (03/16/2026)
H.C. Wainwright reiterated its rating and price target on Savara Inc. (SVRA:NASDAQ), citing a cleared regulatory path for Molbreevi with an August 22, 2026, PDUFA date, no planned FDA Advisory Committee, and accelerating commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals ahead of a potential approval in the rare autoimmune PAP market.
Bothell, WA Bio Co. Poised for 17-20% Revenue Growth in 2026 as Cell Therapy Market Expands (03/13/2026)
BioLife Solutions Inc. (BLFS:NASDAQ) reported strong 2025 results. The company is now a pure-play cell processing business, expecting double-digit growth driven by expanding cell and gene therapy adoption, according to an H.C. Wainwright & Co. research note.
Analyst Maintains Spec Buy on Biotech After Interim SAT-3247 DMD Data (03/11/2026)
Leede Financial maintained its rating on Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ), with a US$16.00 price target following updated interim Phase II SAT-3247 data from the TRAILHEAD trial in Duchenne muscular dystrophy.
A New Infection Control Platform Launched (03/11/2026)
John Newell of John Newell & Associates shares his thoughts on BioLargo Inc. (BLGO:OTCQX) to explain why he thinks the stock is a Speculative Buy.
Medical Co.'s TULSA-PRO Installed Base Growth and CAPTAIN Trial Data Could Accelerate Adoption in 2026" (03/09/2026)
Leede Financial maintained its rating on Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), citing strong TULSA-PRO capital sales, expanding installed base, and upcoming CAPTAIN trial results at EAU meeting as key catalysts.
Cannabis Producer Moves to the TSX as Analyst Flags Major Expansion Potential (03/09/2026)
Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE) began trading on the Toronto Stock Exchange on March 2 after graduating from the TSX Venture Exchange. Atrium Research initiated coverage with a BUY rating and CA$3.00 target, citing best-in-class EBITDA margins of 29%.
Target Raised on CA Pharma Co. as EBITDA Margins Sustain Upward Trajectory (03/06/2026)
Leede Financial maintains its current rating on CareRx and raised its target price, following FQ425 results showing continued sequential improvement in EBITDA, margins, and operating cash flow.
Record Profits, a Vape Market Landgrab, and a CA$250M Facility Bought for CA$27M (03/05/2026)
Atrium Research initiated coverage on Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE), citing the company's dominant position in Quebec's new vape category, best-in-class EBITDA margins of 29%, and a capital-efficient expansion path at its Valleyfield facility that could unlock 100,000 kg of annual production capacity by FY30.
Biotech With Groundbreaking Diabetes Treatment Secures CA$7.1M Breakthrough Financing (03/05/2026)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) successfully secured financing transactions totaling CA$7.1 million, significantly bolstering the company's financial stability. Find out how one analyst rates the stock.
More Archives
2025Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
